medigraphic.com
Colegio de Medicina Interna de México.

2020, Número 3

<< Anterior Siguiente >>

Med Int Mex 2020; 36 (3)


Consenso multidisciplinario de diagnóstico, manejo farmacológico y no farmacológico de la osteoartritis y el papel del sulfato de glucosamina cristalino de prescripción como una nueva opción terapéutica

Díaz-Borjón A, d’Hyver-de las Deses C, Espinosa-Morales R, Galleli L, García-Cué B, Gómez-Miranda JE, Gutiérrez-Gómez JJ, Maldonado-García B, Méndez-Medina CA, Robles-San Román M, Santillán-Barrera E, Tito-Hernández H, Aldrete-Velasco J, Yee-Ben AN

Idioma: Español
Referencias bibliográficas: 73
Paginas: 365-389
Archivo PDF: 322.47 Kb.


RESUMEN

Este documento reúne recomendaciones de diagnóstico, tratamiento farmacológico y no farmacológico de la osteoartritis de acuerdo con el consenso de un grupo multidisciplinario de médicos mexicanos expertos en el tema. La evidencia analizada que se utilizó para generar las recomendaciones en este documento proviene de una búsqueda sistemática de la bibliografía.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Byers V, Blanco F, Englund M, et al. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthritis Cartilage 2015;23(8):1233-1241. doi: 10.1016/j. joca.2015.03.036.

  2. Bellini I, Gringberg P, Constantino G. Generating evidence and understanding the treatment of osteoarthritis in Brazil: a study through Delphi methodology. Clinics 2019;74:e722. http://dx.doi.org/10.6061/clinics/2019/e722.

  3. Neogi T, Zhang Y. Epidemiology of OA. Rheum Dis Clin North Am 2013;39(1):1-19. doi: 10.1016/j.rdc.2012.10.004.

  4. Espinosa-Morales R, Alcántar-Ramírez J, Arce-Salinas J, et al. Reunión multidisciplinaria de expertos para el diagnóstico y tratamiento de la osteoartritis. Actualización basada en evidencias. Med Int Méx 2018;34(3):443-476. http:// dx.doi.org/10.24245/mim.v34i3.1433.

  5. Meza G, Aldrete J, Espinosa R, et al. Osteoartrosis: implementación de los algoritmos de diagnóstico y terapéutico vigentes. Rev Med Inst Mex Seguro Soc 2017;55(1):67-75.

  6. Chalem M, Arango E, Díaz ME. Recomendaciones sobre diagnóstico, prevención y tratamiento farmacológico y no farmacológico de la osteoartritis (OA) de rodilla. Rev Col Med Fis Rehab 2017;27(2):160-184.

  7. Medina-Chávez, JH. Envejecimiento de la población y necesidad de la intervención interdisciplinaria. Rev Enferm Inst Mex Seguro Soc 2015;23(1):1-2.

  8. Subervier L. Empleo del ejercicio en la fisioterapia como tratamiento de la osteoartrosis de rodilla en adultos mayores. An Med (Mex) 2017; 62 (1): 44-53.

  9. Mas X. Definición, etiopatogenia, clasificación y formas de presentación. Aten Primaria 2014;46(1):3-10. DOI: 10.1016/S0212-6567(14)70037-X.

  10. Xia B, Chen D, Zhang J. Osteoarthritis pathogenesis: A review of molecular mechanisms. Calcif Tissue Int 2014;95:495-505. doi: 10.1007/s00223-014-9917-9.

  11. Mobasheri A, Mattaa C, Zákány R, et al. Chondrosenescence: Definition, hallmarks and potential role in the pathogenesis of osteoarthritis. Maturitas 2015;80:237-244. doi: 10.1016/j.maturitas.2014.12.003.

  12. Sánchez MA. Artrosis. Etiopatogenia y tratamiento. An Real Acad Med Cir Vall 2013;50:181-203.

  13. Loeser RF, Goldring SR, Scanzello CR, et al. Osteoarthritis: A disease of the joint as an organ. Arthritis Rheum 2012; 64(6):1697-1707. doi: 10.1002/art.34453.

  14. Altman R, Asch R, Bloch D. Development of criteria for the classification and reporting of OA. Classification of OA of the knee. Arthr Rheum 1986;29:1039-1049. doi: 10.1002/ art.1780290816.

  15. Altman R. Criteria for classification of clinical osteoarthrosis. J Rheumat 1991;18(27):10-12.

  16. Altman R, Alarcón G, Appelrouth D. The American College of Rheumatology criteria for the classification and reporting of OA of the hand. Arth Rheum 1990.

  17. Bijlsma JWJ, Berenbaum F, Lafeber FPJ. Osteoarthritis: an update with relevance for clinical practice. Lancet 2011;377:2115-26. doi: 10.1016/S0140-6736(11)60243-2.

  18. Kuyinu EL, Narayanan G, Nair L, et al. Animal models of osteoarthritis: classification, update, and measurement of outcomes. J Orthopaed Surg Res 2016;11:19. doi: 10.1186/ s13018-016-0346-5.

  19. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: A health status instrument for measuring clinically important patient-relevant outcomes following total hip or knee arthroplasty in osteoarthritis. J Orthop Rheumatol 1988;15(12):1833-1840.

  20. McConnell S, Kolopack P, Davis AM. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC): A review of its utility and measurement properties. Arthritis Rheum 2001;45(5):453- 461. doi: 10.1002/1529-0131(200110)45:5<453::aidart365> 3.0.co;2-w.

  21. Roos E, Roos H, Lohmander L, et al. Knee Injury and Osteoarthritis Outcome Score (KOOS). Development of a selfadministered outcome measure. JOSPT 1998; 78(2):88-96. doi: 10.2519/jospt.1998.28.2.88.

  22. Vaquero J, Giuseppe U, Forriol F, et al. Reliability, validity and responsiveness of the Spanish version of the Knee Injury and Osteoarthritis Outcome Score (KOOS) in patients with chondral lesion of the knee. Knee Surg Sports Traumatol Arthrosc 2012; 22(1):104-108. doi: 10.1007/s00167-012-2290-1.

  23. Delgado G. Evaluación del cartílago articular con resonancia magnética. Rev Chil Radiol 2009;15(1):s39-s44. http:// dx.doi.org/10.4067/S0717-93082009000400006.

  24. American Academy of Orthopaedic Surgeons (AAOS). Treatment of osteoarthritis of the knee, evidence-based guideline. AAOS, Rosemont (Illinois, USA), 2nd ed., 2013.

  25. McAlindon TE, Bannuru RR, Sullivan MC. OARSI guidelines for the non-surgical management of knee Osteoarthritis. Osteoarthritis Cartilage 2014;22:363-388. doi: 10.1016/j. joca.2014.01.003.

  26. Hochberg MC, Altman RD, Toupin-April K, Benkhalti M, Guyatt G, McGowan J. American College of Rheumatology 2012 Recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res 2012;64(4):465-74. doi: 10.1002/acr.21596.

  27. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. European League Against Rheumatism (EULAR) evidence-based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81. doi: 10.1136/ard.2004.028886.

  28. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al. European League Against Rheumatism (EULAR) Recommendations 2003: an evidence-based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55. doi: 10.1136/ ard.2003.011742.

  29. Nymand Z, Dideriksen D, Bjarke H, et al. Acetaminophen for chronic pain: A systematic review on efficacy. Basic Clinical Pharmacol Toxicol 2016;118:184-189. doi: 10.1111/ bcpt.12527.

  30. Da Costa BR, Reichenbach S, Keller N, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network metaanalysis. Lancet 2017;390:e21-33. doi: 10.1016/S0140- 6736(17)31744-0.

  31. Reed K, Collaku A, Moreira S. Efficacy and safety of twice-daily sustained-release paracetamol formulation for osteoarthritis pain of the knee or hip: A randomized, double-blind, placebo-controlled, twelve-week study. Current Medical Research and Opinion 2017;34(4):689-699. doi: 10.1080/03007995.2017.1417245.

  32. Roberts E, Delgado V, Buckner S, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 2016;75:552-559. doi: 10.1136/annrheumdis-2014-206914.

  33. Muñoz-García A, Andrade RJ. Paracetamol e hígado. Rev Esp Enferm Dig 2011; 103(5): 276.

  34. Bruyère O, Honvoa G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthr Rheum 2019:1-14. doi: 10.1016/j.semarthrit.2019.04.008.

  35. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;5(8):1331-46. doi: 10.1111/j.1532-5415.2009.02376.x.

  36. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010;85(5):451- 8. doi: 10.4065/mcp.2009.0534.

  37. Schweighardt A, Juba K. A systematic review of the evidence behind use of reduced doses of acetaminophen in chronic liver disease. J Pain Palliat Care Pharmacother 2018;32(4):226-239. doi: 10.1080/15360288.2019.1611692.

  38. Gallelli L, Galasso O, Falcone D, et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. Osteoarthritis Cartilage 2013; 21:1400-1408. doi: 10.1016/j.joca.2013.06.026.

  39. Gregori D, Giacovelli G, Minto C, et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis a systematic review and meta-analysis. JAMA 2018;320(24):2564-2579. doi: 10.1001/jama.2018.19319.

  40. Shin S. Safety of celecoxib versus traditional nonsteroidal anti-inflammatory drugs in older patients with arthritis. J Pain Res 2018;11:3211-3219.

  41. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375(26):2510-2529. doi: 10.1056/ NEJMoa1611593.

  42. Zweers MC, de Boer TN, van Roon J, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther 2011;13:239. doi: 10.1186/ar3437.

  43. Feng X, Tian M, Zhang W, et al. Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS ONE 2018;13(1):e0190798. doi: 10.1371/journal.pone.0190798.

  44. Huang WN, Tso T. Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly. Bosn J Basic Med Sci 2018;18(1):87-94. doi: 10.17305/bjbms.2017.2214.

  45. Rannou F, Pelletier JP, Martel-Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthr Rheum 2016;45: S18-S21. doi: 10.1016/j.semarthrit. 2015.11.007.

  46. Alcántara Montero A, Sánchez Carnerero CI. ¿Existe evidencia científica para el empleo de la capsaicina tópica en el dolor de la osteoartritis? Semergen 2016. DOI: 10.1016/j. semerg.2016.01.003.

  47. De Silva V, El-Metwally A, Ernst E, et al. Evidence for the efficacy of complementary and alternative medicines in the management of osteoarthritis: a systematic review. Rheumatology 2011; 50:911-920. doi: 10.1093/rheumatology/ keq379.

  48. Chappell A, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Practice 2011;11(1):33- 41. doi: 10.1111/j.1533-2500.2010.00401.x.

  49. Maricar N, Parkes MJ, Callaghan MJ, et al. Structural predictors of response to intra-articular steroid injection in symptomatic knee osteoarthritis. Arthritis Research & Therapy 2017;19:88.

  50. González S, Soto M. Eficacia del ácido hialurónico en el tratamiento de las enfermedades articulares. Rev Cubana de Reumatol 2018;20(3):e34.

  51. Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheuma 2015;45(2):140-149. doi: 10.1016/j.semarthrit. 2015.04.011.

  52. Wehling P, Evans C, Wehling J, et al. Effectiveness of intra-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskel Dis 2017;9(8):183-196. doi: 10.1177/1759720X17712695.

  53. Campbell K, Erickson BJ, Saltzman BM, et al. Is local viscosupplementation injection clinically superior to other Therapies in the treatment of osteoarthritis of the knee: A systematic review of overlapping meta-analyses. Arthroscopy 2015;31(10):2036-2045. doi: 10.1016/j. arthro.2015.03.030.

  54. Bruyère O, Cooper C, Al‑Daghri NM. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 2018; 30:111-117. doi: 10.1007/s40520-017-0861-1.

  55. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Welch V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2009;(2):CD002946. doi: 10.1002/14651858.CD002946.pub2.

  56. Persiani S, Roda E, Rovati LC, et al. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005;13:1041-1049. doi: 10.1016/j. joca.2005.07.009.

  57. Saengnipanthkul S, Waikakul S, Rojanasthien S, et al. Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment. Int J Rheum Dis 2019. doi: 10.1111/1756- 185X.13068.

  58. Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: A Meta-Analysis of Placebo-Controlled Trials. Arthritis Care Res 2014;66(12):1844-1855. doi: 10.1002/acr.22376.

  59. Scholtissen S, Bruyère O, Neuprez A, et al. Glucosamine sulphate in the treatment of knee osteoarthritis: cost-effectiveness comparison with paracetamol. Int J Clin Pract 2010;64(6):756-762. doi: 10.1111/j.1742- 1241.2010.02362.x.

  60. Reginster JY, Dudler J, Blicharski T, et al. Pharmaceuticalgrade chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: The ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT). Ann Rheum Dis 2017;76:1537-1543. doi: 10.1136/annrheumdis-2016-210860.

  61. Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no Superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis. A six-month multicenter, randomized, doubleblind, placebo-controlled clinical trial. Arthritis Rheumatol 2017;69(1):77-85. doi: 10.1002/art.39819.

  62. Altman, R. Glucosamine therapy for knee osteoarthritis: pharmacokinetic considerations. Expert Rev Clin Pharmacol 2009;2(4):359-371. oi: 10.1586/ecp.09.17.

  63. Jackson CG, Plaas AH, Sandy JD, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010;18(3):297-302. doi: 10.1016/j. joca.2009.10.013.

  64. Christiansen BA, Bhatti S, Goudarz R, et al. Management of osteoarthritis with avocado/soybean unsaponifiables. Cartilage 2014;6(1):30-44. oi: 10.1177/1947603514554992.

  65. Honvo G, Reginster JY, Rabenda V, et al. Safety of symptomatic slow-acting drugs for osteoarthritis: Outcomes of a systematic review and meta-analysis. Drugs Aging 2019;36(1):S65-S99. doi: 10.1007/s40266-019-00662-z.

  66. Panova E, Jones G. Benefit–risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf 2015;38(3):245- 252. doi: 10.1007/s40264-015-0266-z.

  67. Pavelka K, Bruyère O, Cooper C, et al. Diacerein: Benefits, risks and place in the management of osteoarthritis. An opinion-based report from the ESCEO. Drugs Aging 2016; 33:75-85. doi: 10.1007/s40266-016-0347-4.

  68. Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis (Review). Cochrane Database Syst Rev 2014;(2):CD005117. doi: 10.1002/14651858.CD005117. pub3.

  69. Rabago C, Waimann CA, Marengo MF, et al. Eficacia y costo-utilidad de primer reemplazo total de cadera y rodilla en pacientes con osteoartritis. Rev Argent Reumatol 2017;28(4): 9-17.

  70. Hernández U, Velásquez J, Lara C, et al. Comparación de la eficacia ejercicio terapéutico isocinético vs isométrico en pacientes con artrosis de rodilla. Reumatol Clin 2012;8(1):10. DOI: 10.1016/j.reuma.2011.08.001

  71. Østerås N, Kjeken I, Smedslund, et al. Exercise for hand osteoarthritis. Cochrane Database Syst Rev. 2017(1): CD010388. doi: 10.3899/jrheum.170424.

  72. Østerås N, Hagen K.B, Grotle M. Limited effects of exercises in people with hand osteoarthritis: results from a randomized controlled trial. Osteoarthritis Cartilage 2014;22:1224- 1233. doi: 10.1016/j.joca.2014.06.036.

  73. Hennig T, Hæhre L,Tryving V, et al. Effect of home-based hand exercises in women with hand osteoarthritis: a randomised controlled trial. Ann Rheum Dis 2014;0:1-8. doi: 10.1136/annrheumdis-2013-204808.




2020     |     www.medigraphic.com